spacer
home > > winter 2020 > a scalable solution
PUBLICATIONS


A Scalable Solution




A key issue for small and medium-sized enterprises (SMEs) in life science is the optimal utilisation of their limited resources for moving their product pipeline through clinical development, and launching and marketing their approved products. This is further heightened as both clinical trials and post-marketing activities continue to grow in complexity and scope due to stringent regulatory pressures, patient involvement, and globalisation. Regardless, companies face overwhelming pressure to get their product to market as quickly as possible.

Clinical trials are typically outsourced end-to-end to full-service CROs. SMEs may select CROs for their niche patient recruitment capabilities in certain geographies and therapeutic areas/indications. As a result, some CROs may not always have the required level of expertise and experience in other aspects of clinical trials, such as data management, statistical design and analysis, medical writing, and regulatory submissions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Susan Najjar at Covance has over 25 years of industry experience with several years in senior leadership and consulting positions. Susan oversaw global marketing activities for Thermo Fisher Scientificís informatics division, developing growth strategies and implementing innovative marketing programmes. Prior to Thermo, she was accountable for establishing the Gillette Companyís North American Blades and Razors forecasting and planning, executing software product launches at Sun Microsystems, and consulting senior pharma executive teams at Deloitte & Touche. Susan has an MS in Biochemical Engineering from Tufts University, US, and an MBA from MIT Sloan, US.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Restructure Announcement at Illingworth

As a rapidly growing company, Illingworth Research Group (Illingworth) has reflected on its goals, accomplishments and ambitious future growth plans. This has allowed us to consider opportunities for staff to explore their own growth and development possibilities within a rapidly changing landscape. With that in mind, Illingworth are announcing some significant and exciting changes to our organization. Illingworth remain committed to making patient involvement in clinical trials as stress free as possible and our strengthened management team and launch of our patient concierge service, PatientGO, in combination with global, mobile research nursing will ensure as many patients as possible have the chance to participate in the development of critical drugs, regardless of their geography or socioeconomic class.
More info >>

White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement